Can-Fite BioPharma (ADR) (CANF)
Develops oral A3AR-targeted drug candidates for psoriasis, liver cancer and metabolic liver disease.
Something off on this page? Send us feedback.
Develops oral drug candidates targeting the A3 adenosine receptor, with pivotal programs in psoriasis and advanced liver cancer. Revenue comes from licensing arrangements, while development, manufacturing and eventual commercialization rely on external providers and territorial partners.
Develops orally bioavailable small molecules targeting the A3 adenosine receptor, which the company says is highly expressed in inflammatory and cancer cells but low in normal cells. Piclidenoson is in a pivotal psoriasis study, while Namodenoson is in a pivotal advanced hepatocellular carcinoma study and is also being studied in MASH and pancreatic cancer.
Runs development plans with a five-person Israel-based team and outsources preclinical work, trials and manufacturing to contract organizations. Its model combines upfront license payments, milestones, royalties and finished-product arrangements under territorial agreements, rather than product sales.
Retains core clinical development while regional partners handle local approval, distribution and eventual sales. No candidate had marketing approval or commercial product sales in the latest annual filing.
Company facts
Unavailable right now.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Dec 31, 2025Cash & short-term investments $8.5M · Total debt $71.0K · Total assets $9.5M · Shareholders' equity $5.6M
- Revenue
- $101.5K
- Operating income
- −$2.5M
- Net income
- −$2.5M
No dividends on record.
| Institutions14 holders · as of Dec 31, 2025 | 45.56% | 29.8K ADS | |
| Otherremainder | 54.44% | 35.6K ADS |
65.5K ADS (1 ADS = 2 ordinary shares) as of Sep 3, 2026 · institutions as of Dec 31, 2025 · holders as of their latest filing
Two share counts disagree (65.5K in the company's Sep 3, 2026 report, 1.31M elsewhere); stakes use the report.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Rhumbline AdvisersInstitution | 21.53% | 281,881 ADS | 13Fas of Dec 31, 2025 |
Jane Street Group, LLCInstitution | 15.66% | 205,004 ADS | 13Fas of Dec 31, 2025 |
Advisor Group Holdings, Inc.Institution | 2.75% | 36,000 ADS | 13Fas of Dec 31, 2025 |
UBS Group AGInstitution | 1.60% | 20,942 ADS | 13Fas of Dec 31, 2025 |
XTX Topco LtdInstitution | 1.43% | 18,686 ADS | 13Fas of Dec 31, 2025 |
| See all 22 → | |||
13F — a manager's quarterly holdings
Insider tradesForm 4
Nothing filed in the last 12 months.
- Bristol-Myers Squibb
Oral psoriasis therapy and established HCC treatment alternatives.
- Amgen
Direct oral psoriasis comparator in the systemic-treatment pathway.
- Exelixis
Approved post-treatment HCC therapy in the advanced-disease setting.
- AstraZeneca (ADR)
First-line HCC immunotherapy shaping treatment sequencing.
- Novartis (ADR)
Scaled IL-17 biologic alternative for systemic plaque psoriasis.
- Eli Lilly
IL-17 biologic for moderate-to-severe plaque psoriasis.
- Madrigal Pharmaceuticals
Approved liver-directed therapy for MASH with fibrosis.
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Can-Fite BioPharma (ADR) | $2.39 | +0.85% | $3.1M | — | — | 14.1 | +13.4% |
| Bristol-Myers Squibb | $67.65 | −0.01% | $138.21B | 14.9 | 10.6 | 2.8 | +5.7% |
| Amgen | $443.00 | +0.04% | $239.00B | 27.5 | 18.9 | 6.3 | +9.7% |
| Exelixis | $59.11 | +0.96% | $14.71B | 18.3 | 15.8 | 6.0 | +10.6% |
| AstraZeneca (ADR) | $163.48 | +1.13% | $250.67B | 24.3 | 15.2 | 4.1 | +6.4% |
| Novartis (ADR) | $162.45 | +0.01% | $308.79B | 24.5 | 17.3 | 5.6 | +0.9% |
| Eli Lilly | $1,167.77 | +0.72% | $1.09T | 38.9 | 28.4 | 13.7 | +47.7% |
| Madrigal Pharmaceuticals | $546.41 | +1.43% | $12.64B | — | — | 9.8 | +71.2% |
| Median | 24.4 | 16.6 | 6.0 | +9.7% |